Entrada Therapeutics (TRDA) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Delivery platform

• Cyclic cell-penetrating peptides, called EEVs, cross cell membranes, escape early endosomes and deliver payloads to intracellular targets; EEV pharmacokinetics shape drug-body interactions.

• Initial therapeutic focus is neuromuscular disease, including DMD exon 44 and 45 programs and the partnered DM1 program VX-670 with Vertex.

Upcoming clinical catalysts

• Four significant clinical readouts are expected from the conference date through H1 2027: Vertex’s partnered DM1 interim phase I/II results and three DMD program updates.

• ELEVATE-44 cohort 1 open-label data are expected before year-end, after patients have received 8–9 months of treatment and at least six 6 mg/kg doses.

• ELEVATE-44 cohort 2 data are expected in Q1 2027 at 12 mg/kg; exon 45 cohort 2 data are expected by the end of H1 2027.

DMD efficacy, dosing and safety

• ELEVATE-45 cohort 1 at 5 mg/kg was designed primarily to assess safety; some dystrophin was observed, though little production was expected in the young patients with low baseline levels.

• The 5 mg/kg exon 45 dose is one-sixth of casimersen’s 30 mg/kg dose; the planned six-week interval compares with casimersen’s weekly dosing.

• Exon 45 cohort 2 is intended to test dose response; a potential third cohort at 15 mg/kg depends on cohort 2, with significant dose response expected somewhere between 10 and 15 mg/kg.

• Low-dose exon 44 cohort 1 showed Time to Rise and velocity benefit despite low dystrophin; access to quiescent satellite cells is a hypothesis being tested in cohort 2.

• Safety was described as holding at higher doses; no participants have dropped out, and no material negative renal effects have been observed, though treatment-emergent adverse events occurred.